This article is more than 5 years old. Information may no longer be current.
Incidence of noninfectious vitritis, infectious endophthalmitis after anti-VEGF injections low
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — The rates of noninfectious vitritis and infectious endophthalmitis after anti-VEGF injections were low but varied between anti-VEGF agents, a speaker said here.
“The results suggest a difference in rates of noninfectious vitritis depending on the anti-VEGF agent used. Aflibercept had more frequency,” Andre P. Muralha, MD, said at the Retina World Congress.
Muralha presented the results of a retrospective monocentric study evaluating the incidences of noninfectious vitritis and infectious endophthalmitis after intravitreal injections of anti-VEGF agents.
Participants were followed for 6 months and analyzed for rates of infection. In total, 9,338 intravitreal injections were screened, including 4,846 ranibizumab injections and 4,492 aflibercept injections. All injections were performed using a standardized sterile technique in an operating room, he said.
Twenty cases resulted in noninfectious vitritis, two after ranibizumab injections and 18 after aflibercept injections. Four cases resulted in infectious endophthalmitis, two after ranibizumab injections and two after aflibercept injections.
“Even though research showed the outcomes after endophthalmitis were really poor, in our cases the prompt pars plana vitrectomy and antibiotic injections resulted in better visual outcomes,” Muralha said. – by Robert Linnehan
Reference:
Muralha A. Incidence and outcomes of non-infectious vitritis and infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Presented at: Retina World Congress; March 21 to 24, 2019; Fort Lauderdale, Fla.
Disclosure: Muralha reports no relevant financial disclosures.